|
WO2021067864A1
|
|
Zinc finger protein transcription factors for treatment of prion disease
|
|
WO2021067871A1
|
|
Zinc finger protein transcription factors for repressing alpha-synuclein expression
|
|
WO2021011436A1
|
|
Separation and quantification of empty and full viral capsid particles
|
|
WO2020237045A1
|
|
Controlled transgene expression in regulatory t cells
|
|
WO2020219988A2
|
|
Engineering aav
|
|
US2020339638A1
|
|
Modulators of Chromosome 9 Open Reading Frame 72 Gene Expression and Uses Thereof
|
|
US2020316116A1
|
|
Method for the treatment of beta-thalassemia
|
|
TW202045529A
|
|
Compositions and methods for producing recombinant aav
|
|
WO2020150338A1
|
|
Htt repressors and uses thereof
|
|
US2020239911A1
|
|
Methods and compositions for the treatment of fabry disease
|
|
WO2020097188A1
|
|
Identification of molecules for inhibition of nk-mediated cell killing
|
|
WO2020072677A1
|
|
Methods and compositions for modulation of tau proteins
|
|
WO2020072684A1
|
|
Engineered genetic modulators
|
|
WO2020061161A1
|
|
Programmed cell death 1 (pd1) specific nucleases
|
|
CA3109592A1
|
|
Engineered target specific base editors
|
|
WO2020050947A2
|
|
Enzymatic assays for quantifying therapy in subjects with mucopolysaccharidosis type i or ii
|
|
WO2020162978A1
|
|
Method for the treatment of mucopolysaccharidosis type i
|
|
WO2020033525A1
|
|
Method for the treatment of mucopolysaccharidosis type ii
|
|
US2020071743A1
|
|
Enzymatic assays for quantifying therapy in subjects with mucopolysaccharidosis type i or ii
|
|
CA3105382A1
|
|
Improved clinical parameters by expression of factor viii
|
